These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30597637)

  • 1. Production of a novel N-terminal PEGylated crisantaspase.
    Torres-Obreque K; Meneguetti GP; Custódio D; Monteiro G; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    Biotechnol Appl Biochem; 2019 May; 66(3):281-289. PubMed ID: 30597637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
    Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
    Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel site-specific PEGylated L-asparaginase.
    Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase.
    Torres-Obreque K; Kleingesinds EK; Santos JHPM; Carretero G; Rabelo J; Converti A; Monteiro G; Pessoa A; Rangel-Yagui CO
    Prep Biochem Biotechnol; 2024 Apr; 54(4):503-513. PubMed ID: 37698175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
    Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
    Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noncovalent PEGylation of L-asparaginase using PEGylated polyelectrolyte.
    Kurinomaru T; Shiraki K
    J Pharm Sci; 2015 Feb; 104(2):587-92. PubMed ID: 25354692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A PEGylation technology of L-asparaginase with monomethoxy polyethylene glycol-propionaldehyde.
    Wang B; Cao Y; Chi S; Lou D
    Z Naturforsch C J Biosci; 2012; 67(5-6):312-8. PubMed ID: 22888537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
    Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.
    Modi T; Gervais D
    Invest New Drugs; 2022 Feb; 40(1):21-29. PubMed ID: 34468906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase.
    Soares AL; Guimarães GM; Polakiewicz B; de Moraes Pitombo RN; Abrahão-Neto J
    Int J Pharm; 2002 Apr; 237(1-2):163-70. PubMed ID: 11955814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase activities during intensified treatment with pegylated
    Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
    Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended enzymatic stability of reconstituted lyophilized PEG-asparaginase in vials.
    Viña-Romero MM; Ramos Díaz R; González García J; Nazco-Casariego G; Díaz-Vera J; Gutiérrez-Nicolás F
    J Oncol Pharm Pract; 2021 Jul; 27(5):1102-1105. PubMed ID: 32854574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
    Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
    Schnuchel A; Radcke C; Theobald L; Doeding S
    PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering Cell-Free Protein Synthesis for High-Yield Production and Human Serum Activity Assessment of Asparaginase: Toward On-Demand Treatment of Acute Lymphoblastic Leukemia.
    Hunt JP; Wilding KM; Barnett RJ; Robinson H; Soltani M; Cho JE; Bundy BC
    Biotechnol J; 2020 Apr; 15(4):e1900294. PubMed ID: 31904183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
    Avramis VI; Tiwari PN
    Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetic studies of three asparaginase preparations.
    Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
    J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.